Sanofi's Origimm takeover acquires skin microbiome-targeting candidate for acne vaccine 03-Dec-2021 By Will Chu Sanofi is to acquire Origimm Biotechnology in a move that gives the pharma giants a candidate to develop a first-in-class acne vaccine, which targets the skin microbiome and bacterial antigens that cause the skin condition.
